BioSpace News Archive

Nicox SA provided details of a U.S. market survey evaluating the commercial potential of NCX 470, a nitric oxide -donating bimatoprost, in development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension and estimated potential global annual net sales for NCX 470.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it has submitted a first Clinical Trial Application for OTOF-GT to the UK’s Medicines and Healthcare products Regulatory Agency.

Biophytis SA announced that it has filed for approval on the Food and Drug Administration portal to launch its SARA-31 program in the U.S., the first ever Phase 3 study in sarcopenia.

Fulcrum Therapeutics, Inc. today announced that it has entered into a worldwide, exclusive license agreement with CAMP4 Therapeutics Corp., whereby Fulcrum will advance the discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia (DBA).

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced that seven abstracts will be presented as oral presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 28 to August 1 in Seattle.

Societal CDMO, Inc. announced that it has been selected by Spinnaker Biosciences, Inc., to execute CDMO services in support of the company’s clinical development of a novel therapeutic candidate.

Dr. Redfield Joins Scientific Advisory Board as BPGBio Advances its Deep Portfolio of AI-Developed Late-Stage Therapeutics and Diagnostics.

MyoPax Receives Rare Pediatric Disease Designation from FDA for Breakthrough Regenerative Cell Product in Exstrophy-Epispadias Complex.

Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, announced the appointment of Hillary Bochniak as Chief Human Resources Officer, effective July 10, 2023.

Evelo Biosciences, Inc. today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”) at a purchase price of $2.31 per share.